diabetes
From The Long Sepsis, an encyclopedia of a world that didn't happen
Diabetes is a chronic metabolic condition in which the body cannot regulate blood glucose effectively, either through insufficient insulin production or cellular resistance to insulin's effects. In wealthy nations of the early 21st century, diabetes affects roughly 8-10 percent of the adult population, making it one of the most common chronic diseases. Yet in the Long Sepsis, the threat posed by diabetes has been fundamentally reshaped by the absence of reliable systemic antibacterial treatment, so that clinical management has become less a matter of glucose control and more a matter of infection prevention and careful quarantine.
The diagnosis and initial management of diabetes in this era differ little from the essential facts: fasting blood glucose measurement, glucose tolerance testing, and dietary modification remain the standard approach. Insulin, synthesized commercially since the 1920s, is available to diabetic patients in wealthy nations, though rationing and cost restrictions apply in many regions. A diabetic patient with access to insulin and regular dietary supervision can maintain reasonable glucose control and avoid acute ketoacidosis, the life-threatening acidification that accompanies severe insulin deficiency.
Yet the clinical course of a diabetic patient in the Long Sepsis diverges sharply from outcomes in nations with systemic antimicrobial treatment. The reason is not glucose itself, but the complications that arise from it. Chronically elevated blood glucose impairs the function of antibodies and white blood cells, making diabetic patients far more susceptible to bacterial infection. In a world where azo drugs are the only systemic antibacterial class and their efficacy against many organisms is marginal, this susceptibility becomes a death sentence.
Diabetic foot infections are the clearest illustration of this clinical reality. A small wound—a blister from poorly fitting shoes, a cut from walking barefoot, a minor surgical intervention—becomes infected in a diabetic patient at rates five to ten times higher than in non-diabetic individuals. In nations with effective antimicrobial chemotherapy, such infections are treated aggressively with systemic drugs and often resolved. In the Long Sepsis, they are treated with local debridement, asepsis maximalism protocols, and serum therapy if the infection becomes systemic—but these interventions often arrive too late.
The result is gangrene, tissue death from bacterial invasion and vascular compromise. Amputation remains common, but many amputations occur not because of glucose dysregulation but because of untreatable infection. Ministry of Health statistics from the Geneva Sanitary Bureau, compiled from 1980 onward, show that roughly 40 percent of lower-limb amputations in diabetic patients occur secondary to bacterial infection rather than to glucose-related vascular disease alone. The proportion is higher in nations with limited access to serum therapy.
Urinary tract infections, pneumonia, skin abscesses, and meningitis occur at elevated rates in diabetic populations. Each represents an opportunity for progression to septicaemia, bacterial infection of the bloodstream, which remains nearly universally fatal despite the availability of azo drugs. A diabetic patient who develops bacteraemia has roughly a 60-70 percent mortality rate even with maximal serum therapy intervention, according to clinical trial data compiled by the Infectious Disease Research Centre in Cambridge between 1975 and 1990.
References
- 1.Statistical Methods in Clinical Bacteriology and Their Application to Serum Therapy Trials]]: Geneva Sanitary Bureau epidemiological compilation, 1980–1995, held at the Bureau's archives in Geneva
- 2.The Rise of Serum Therapy: A Medical History]]: Survey of diabetic infection outcomes and serum therapy efficacy, Cambridge Infectious Disease Research Centre, 1975–1990
- 3.Bacterial Genetics and the Limits of Chemical Therapy: A 1981 Retrospective]]: Analysis of resistant organism selection in high-infection populations, with particular focus on diabetic patient cohorts
- 4.Archives of the Institute for the History of Bacteriology: Statistical Methods and Clinical Trial Records]]: Diabetic infection trial protocols and outcome data, 1970–1985